• Logout
  • Profile
  • PortuguÍs
  •  
  • 0
  •  
     
    Category: Date -
    (e.g. ANVISA, AstraZeneca, insulin, S„o Paulo, public, drug pricing )
       BMS cuts HIV drug price in Peru after compulsory license threat  
    2015-07-14 - Bristol-Myers Squibb (BMS) is reported to have agreed to a 35% price reduction to its HIV drug Reyataz (atazanavir) in Peru, after protracted negotiations with the Ministry of Health (MoH). The price of the drug, an antiretroviral drug of the protease inhibitor (PI) class, has been cut from PEN 29.17 (price paid per tablet in 2013) to PEN 18.96 (USD 8.99 to USD 5.84), which will benefit Peru's population of 1,800 HIV/AIDS sufferers.

    Negotiations with BMS reportedly carried on for the past 12 months, and reportedly saw the MoH declare securing supplies of atazanavir as in the public interest, thereby making the drug eligible for compulsory licensing under World Trade Organization rules. The source notes that Reyataz's patent is valid until 2019 in Peru.
    Recent news    More>>
    Brazilís Fiocruz releases 192 drug batches for SUS during Q1í19 2019-05-14
    BIís COPD combination therapy bags approval in Brazil 2019-05-14
    ANVISA nods Allerganís MDD drug Fetzim/Fetzima in Brazil 2019-05-14
    ANVISA and industry stakeholders hone API regulations 2019-05-10
    Brazilís Blau FarmacÍutica plans to reach 15% retail market share in 2019 2019-05-10
    ANVISA concludes drug traceability test in Brazil 2019-05-10
    Sandoz Brazil plans 42 launches by 2023, four biosimilars 2019-05-09
    Related briefs   
    BMSís Opdivo collects eighth cancer indication from Brazilís ANVISA 2019-03-29
    ABIFINA publishes list of drugs patented so far this year in Brazil 2019-03-21
    BMSís Opdivo gains indication for melanoma in Argentina 2019-01-04
    HCV patients pressure Colombiaís MoH for compulsory licenses 2018-11-07
    BMS's Opdivo-Yervoy combo therapy gains indication for kidney cancer in Brazil 2018-10-18
    Gilead maintains discount offer to Brazilís MoH on sofosbuvir alternatives 2018-09-25
    Brazil grants Gilead hepatitis C drug patent 2018-09-19
    Products mentioned:
    Atazanavir
    Companies mentioned:
    Bristol-Myers Squibb
    Policies mentioned:
      May 20, 2019 
             © 2019 GB Information. All Rights Reserved